Padcev/Keytruda Results Could Sweeten Potential Seagen/Merck Deal

Most Observers Still Want More Detailed Data From Urothelial Cancer Study

 
• By Alaric DeArment
Seagen/Astellas announced topline results from the Phase Ib/II study of Padcev/Keytruda in urothelial cancer • Source: Shutterstock

More from Deals

More from Business